Therapy Areas: AIDS & HIV
KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE
8 November 2021 - - US-based pharmaceutical company KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) presented data at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, the company said.

Data presentations included an oral presentation and poster presentation on Phase 2 data for KVD900, KalVista's lead program for oral on-demand treatment of hereditary angioedema attacks.

KVD900 was rapidly absorbed, with measurable concentrations detected within 15 minutes. Plasma levels reached peak concentration within 1 hour of administration.

Median time to symptom improvement was significantly shorter with KVD900 than with placebo (1.6 vs 9.0 hours, p
Login
Username:

Password:


Related Headlines

HDT Bio targets vaccines to specific variants of SARS-CoV2 to slow the spread of COVID-19 and reduce transmission

Venatorx Pharmaceuticals closes Series C financing led by the AMR Action Fund

Prestige signs MOU with Vaxine for supply of Spikogen COVID vaccine and co-development of COVID-19/influenza combo vaccine

Prestige Biopharma Enters MOU with Vaxine for Supply of COVID-19 Vaccine and Co-development of COVID-19/Influenza Combo Vaccine

HDT Bio Doses First Healthy Volunteer in US Phase 1 Trial of Next Generation COVID-19 Variant RNA Vaccine

HDT Bio Corp launches Phase 1 trial in vaccinated and unvaccinated people to evaluate HDT-301 as booster as well as primary vaccine

Novavax announces two booster studies to evaluate its COVID-19 Vaccine, NVX-CoV2373

Bernard Named CEO at Applied BioCode

Chimeron Bio receives NIAID's support to evaluate its lead vaccine candidate CB-106 for COVID-19

Eurofins Viracor, Cornell University Sign Exclusive Licensing Agreement to Expand Access to Ground-Breaking Technologies for Assessing Organ and Tissue Damage in Transplant and COVID-19 Patients

Perrigo Company plc wins FDA approval for OTC use of Nasonex 24HR Allergy

Shionogi reports progress toward start of phase 3 trial of COVID-19 antiviral agent S-217622

Walgreens and Labcorp unveil free at-home COVID-19 PCR test collection kits nationwide

Walgreens and Labcorp Offer At-Home COVID-19 PCR Test Collection Kits at No Cost in US

Aravax Pty Opens US IND for Phase 2 clinical trials of PVX108 Immunotherapy for the Treatment of Peanut Allergy